This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Vanda Pharmaceuticals Inc (VNDA)

NASDAQ: Health Care

Company Income Statement
Dec 2014 Dec 2013 Dec 2012 Dec 2011
Sales 50.16M 33.88M 32.73M 31.27M
Cost of Sales 879.00K 0.00 129.00K 0.00
Gross Operating Profit 49.28M 33.88M 32.60M 31.27M
Selling, General, and Administrative Expenses 84.64M 21.43M 13.88M 11.49M
Research & Development 19.23M 28.19M 45.45M 29.00M
Operating Income before D & A (EBITDA) -54.60M -15.74M -26.73M -9.21M
Depreciation & Amortization 2.96M 2.08M 2.69M 2.86M
Interest Income 0.00 145.00K 561.00K 461.00K
Other Income - Net 77.74M -3.17M 0.00 0.00
Special Income / Charges 0.00 0.00 0.00 0.00
Total Income Before Interest Expenses (EBIT) 20.19M -20.84M -28.86M -11.62M
Interest Expense 0.00 0.00 0.00 0.00
Pre-Tax Income 20.19M -20.84M -28.86M -11.62M
Income Taxes 0.00 0.00 0.00 -444.00K
Minority Interest 0.00 0.00 0.00 0.00
Net Income From Continuing Operations 20.19M -20.26M -27.66M -9.80M
Net Income From Discontinued Operations 0.00 0.00 0.00 0.00
Net Income From Total Operations 20.19M -20.26M -27.66M -9.80M
Extraordinary Income/Losses 0.00 0.00 0.00 0.00
Income From Cum. Effect of Acct. Change 0.00 0.00 0.00 0.00
Income From Tax Loss Carryforward 0.00 0.00 0.00 0.00
Other Gains / Losses 0.00 0.00 0.00 0.00
Total Net Income 20.19M -20.26M -27.66M -9.80M
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
20.19M -20.26M -27.66M -9.80M
Preferred Dividends
Net Income Available To Common 20.19M -20.26M -27.66M -9.80M
Basic EPS from Continuing Ops. 0.58 -0.67 -0.98 -0.35
Basic EPS from Discontinued Ops. 0.00 0.00 0.00 0.00
Basic EPS from Total Operations 0.58 -0.67 -0.98 -0.35
Basic EPS from Extraordinary Inc. 0.00 0.00 0.00 0.00
Basic EPS from Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
Basic EPS from Tax Loss Carryf'd. 0.00 0.00 0.00 0.00
Basic EPS from Other Gains (Losses) 0.00 0.00 0.00 0.00
Basic EPS, Total 0.58 -0.67 -0.98 -0.35
Basic Normalized Net Income/Share 0.58 -0.67 -0.98 -0.35
EPS fr Continuing Ops. 0.55 -0.67 -0.98 -0.35
EPS fr Discontinued Ops 0.00 0.00 0.00 0.00
EPS fr Total Ops. 0.55 -0.67 -0.98 -0.35
EPS fr Extraord. Inc. 0.00 0.00 0.00 0.00
EPS fr Cum Effect of Accounting Change 0.00 0.00 0.00 0.00
EPS fr Tax Loss Carfd. 0.00 0.00 0.00 0.00
EPS fr Other Gains (L) 0.00 0.00 0.00 0.00
EPS, Total 0.55 -0.67 -0.98 -0.35
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0.55 -0.67 -0.98 -0.35
Dividends Paid per Share 0.00 0.00 0.00 0.00
VNDA News

VNDA Vanda Pharmaceuticals Inc

Analysts Ratings for VNDA

Rating Current 1-Mo Ago 2-Mo Ago 3-Mo Ago
Strong Buy 3 3 3 3
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
GET VNDA ANALYST REPORT

Brokerage Partners

VNDA Chatter

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
Real Money Pro

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Trifecta Stocks

Trifecta Stocks analyzes over 4,000 equities weekly to find the elite 1% of stocks that pass rigorous quantitative, fundamental and technical tests.

Product Features:
  • Model portfolio
  • Trade alerts
  • Recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Growth Seeker

Bryan Ashenberg, using sophisticated stock screening and fundamental research, identifies potentially explosive small and mid-cap stocks.

Product Features:
  • Model portfolio
  • Small-cap and mid-cap focus
  • Intraday trade alerts
  • Weekly roundups
Options Profits

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
Top Rated Stocks Top Rated Funds Top Rated ETFs